LOC285629 regulates cell proliferation and motility in colorectal cancer cells

Research output: Contribution to journalArticle

Abstract

Purpose: Colorectal cancer (CRC) is one of the most widely diagnosed cancers in men and women worldwide. With the advancement of next-generation sequencing technologies, many studies have highlighted the involvement of long non-coding RNAs (lncRNAs) in cancer development. Growing evidence demonstrates that lncRNAs play crucial roles in regulating gene and protein expression and are involved in various cancers, including CRC. The field of lncRNAs is still relatively new and a lot of novel lncRNAs have been discovered, but their functional roles are yet to be elucidated. This study aims to characterize the expression and functional roles of a novel lncRNA in CRC. Method: Several methods were employed to assess the function of LOC285629 such as gene silencing, qPCR, proliferation assay, BrdU assay, transwell migration assay, ELISA and protein profiler. Results: Via in silico analyses, we identified significant downregulation of LOC285629, a novel lncRNA, across CRC stages. LOC285629 expression was significantly downregulated in advanced stages (Stage III and IV) compared to Stage I (Kruskal–Wallis Test; p = 0.0093). Further in-house validation showed that the expression of LOC285629 was upregulated in colorectal cancer tissues and cell lines compared to the normal counterparts, but was downregulated in advanced stages. By targeting LOC285629, the viability, proliferative abilities, invasiveness and resistance of colorectal cancer cells towards 5-fluorouracil were reduced. It was also discovered that LOC285629 may regulate cancer progression by targeting several different proteins, namely survivin, BCL-xL, progranulin, PDGF-AA, enolase 2 and p70S6 K. Conclusion: Our findings suggest that LOC285629 may be further developed as a potential therapeutic target for CRC treatment.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalClinical and Translational Oncology
DOIs
Publication statusAccepted/In press - 2 Nov 2017

Fingerprint

Long Noncoding RNA
Cell Movement
Colorectal Neoplasms
Cell Proliferation
Down-Regulation
Neoplasms
Proteins
Phosphopyruvate Hydratase
Gene Silencing
Bromodeoxyuridine
Fluorouracil
Computer Simulation
Enzyme-Linked Immunosorbent Assay
Technology
Gene Expression
Cell Line
Therapeutics

Keywords

  • Colon cancer
  • In silico analysis
  • Long non-coding RNA
  • Motility
  • Proliferation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{54d9b8664b8e44b2a5f51703669c6b12,
title = "LOC285629 regulates cell proliferation and motility in colorectal cancer cells",
abstract = "Purpose: Colorectal cancer (CRC) is one of the most widely diagnosed cancers in men and women worldwide. With the advancement of next-generation sequencing technologies, many studies have highlighted the involvement of long non-coding RNAs (lncRNAs) in cancer development. Growing evidence demonstrates that lncRNAs play crucial roles in regulating gene and protein expression and are involved in various cancers, including CRC. The field of lncRNAs is still relatively new and a lot of novel lncRNAs have been discovered, but their functional roles are yet to be elucidated. This study aims to characterize the expression and functional roles of a novel lncRNA in CRC. Method: Several methods were employed to assess the function of LOC285629 such as gene silencing, qPCR, proliferation assay, BrdU assay, transwell migration assay, ELISA and protein profiler. Results: Via in silico analyses, we identified significant downregulation of LOC285629, a novel lncRNA, across CRC stages. LOC285629 expression was significantly downregulated in advanced stages (Stage III and IV) compared to Stage I (Kruskal–Wallis Test; p = 0.0093). Further in-house validation showed that the expression of LOC285629 was upregulated in colorectal cancer tissues and cell lines compared to the normal counterparts, but was downregulated in advanced stages. By targeting LOC285629, the viability, proliferative abilities, invasiveness and resistance of colorectal cancer cells towards 5-fluorouracil were reduced. It was also discovered that LOC285629 may regulate cancer progression by targeting several different proteins, namely survivin, BCL-xL, progranulin, PDGF-AA, enolase 2 and p70S6 K. Conclusion: Our findings suggest that LOC285629 may be further developed as a potential therapeutic target for CRC treatment.",
keywords = "Colon cancer, In silico analysis, Long non-coding RNA, Motility, Proliferation",
author = "Nasir, {S. N.} and Nadiah Abu and {Ab Mutalib}, {Nurul Syakima} and M. Ishak and Ismail Sagap and Luqman Mazlan and Rose, {I. M.} and {A. Jamal}, {A. Rahman}",
year = "2017",
month = "11",
day = "2",
doi = "10.1007/s12094-017-1788-x",
language = "English",
pages = "1--10",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - LOC285629 regulates cell proliferation and motility in colorectal cancer cells

AU - Nasir, S. N.

AU - Abu, Nadiah

AU - Ab Mutalib, Nurul Syakima

AU - Ishak, M.

AU - Sagap, Ismail

AU - Mazlan, Luqman

AU - Rose, I. M.

AU - A. Jamal, A. Rahman

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Purpose: Colorectal cancer (CRC) is one of the most widely diagnosed cancers in men and women worldwide. With the advancement of next-generation sequencing technologies, many studies have highlighted the involvement of long non-coding RNAs (lncRNAs) in cancer development. Growing evidence demonstrates that lncRNAs play crucial roles in regulating gene and protein expression and are involved in various cancers, including CRC. The field of lncRNAs is still relatively new and a lot of novel lncRNAs have been discovered, but their functional roles are yet to be elucidated. This study aims to characterize the expression and functional roles of a novel lncRNA in CRC. Method: Several methods were employed to assess the function of LOC285629 such as gene silencing, qPCR, proliferation assay, BrdU assay, transwell migration assay, ELISA and protein profiler. Results: Via in silico analyses, we identified significant downregulation of LOC285629, a novel lncRNA, across CRC stages. LOC285629 expression was significantly downregulated in advanced stages (Stage III and IV) compared to Stage I (Kruskal–Wallis Test; p = 0.0093). Further in-house validation showed that the expression of LOC285629 was upregulated in colorectal cancer tissues and cell lines compared to the normal counterparts, but was downregulated in advanced stages. By targeting LOC285629, the viability, proliferative abilities, invasiveness and resistance of colorectal cancer cells towards 5-fluorouracil were reduced. It was also discovered that LOC285629 may regulate cancer progression by targeting several different proteins, namely survivin, BCL-xL, progranulin, PDGF-AA, enolase 2 and p70S6 K. Conclusion: Our findings suggest that LOC285629 may be further developed as a potential therapeutic target for CRC treatment.

AB - Purpose: Colorectal cancer (CRC) is one of the most widely diagnosed cancers in men and women worldwide. With the advancement of next-generation sequencing technologies, many studies have highlighted the involvement of long non-coding RNAs (lncRNAs) in cancer development. Growing evidence demonstrates that lncRNAs play crucial roles in regulating gene and protein expression and are involved in various cancers, including CRC. The field of lncRNAs is still relatively new and a lot of novel lncRNAs have been discovered, but their functional roles are yet to be elucidated. This study aims to characterize the expression and functional roles of a novel lncRNA in CRC. Method: Several methods were employed to assess the function of LOC285629 such as gene silencing, qPCR, proliferation assay, BrdU assay, transwell migration assay, ELISA and protein profiler. Results: Via in silico analyses, we identified significant downregulation of LOC285629, a novel lncRNA, across CRC stages. LOC285629 expression was significantly downregulated in advanced stages (Stage III and IV) compared to Stage I (Kruskal–Wallis Test; p = 0.0093). Further in-house validation showed that the expression of LOC285629 was upregulated in colorectal cancer tissues and cell lines compared to the normal counterparts, but was downregulated in advanced stages. By targeting LOC285629, the viability, proliferative abilities, invasiveness and resistance of colorectal cancer cells towards 5-fluorouracil were reduced. It was also discovered that LOC285629 may regulate cancer progression by targeting several different proteins, namely survivin, BCL-xL, progranulin, PDGF-AA, enolase 2 and p70S6 K. Conclusion: Our findings suggest that LOC285629 may be further developed as a potential therapeutic target for CRC treatment.

KW - Colon cancer

KW - In silico analysis

KW - Long non-coding RNA

KW - Motility

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=85032967246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032967246&partnerID=8YFLogxK

U2 - 10.1007/s12094-017-1788-x

DO - 10.1007/s12094-017-1788-x

M3 - Article

SP - 1

EP - 10

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

ER -